[ad_1]
WALL – Professor of Immunity at the Jackson Laboratory in the United States. Dr Derya Unutmaz evaluated ongoing vaccination studies against the corona virus (Covid-19).
Unutmaz, who participated in the “GüneView” program published in Medyascope, said that despite the increase in the epidemic, success in vaccination studies is promising.
“Actually, we are in a very strange period”, said Unutmaz, “On the one hand, the epidemic is increasing rapidly, but on the other we can say that ‘the light has appeared at the end of the tunnel, the beginning of the end. ‘for this pandemic. Vaccine studies have produced better results than we hoped for. We can say that the 95% protection rate is the best possible rate for a vaccine, as well as two different companies using the same technology. We are in a very promising process for 2021 ”.
‘IT WILL BE LITTLE THIS WINTER’
Journalist Burak Tatari said: “We have a very difficult winter ahead of us due to the coronavirus. This won’t contribute to the winter, right? “Derya Unutmaz stated that the effect of the vaccine during the winter will be limited.
Do not forget: “This winter will make little contribution. Currently the BioNTech company in America has requested consent at the same time in Europe. But this is an urgent request for consent. They currently have a limited supply of the vaccine. About 50-60 million doses, “he said.
Stating that the current amount of the vaccine will be enough for 25 million people, Unutmaz said: “Considering that two doses are given, there are enough vaccines for about 25 million people. This vaccine will be administered primarily to healthcare professionals and, if sufficient, to older people with chronic diseases with very high risk factors. This will have an impact, because relieving health workers is key in this process. “We will start to see the effects of this as of February-March,” he said. (NEWS CENTER)
It might grab your attention
Source link